Skip to main
TNDM

TNDM Stock Forecast & Price Target

TNDM Analyst Ratings

Based on 18 analyst ratings
Buy
Strong Buy 22%
Buy 28%
Hold 50%
Sell 0%
Strong Sell 0%

Bulls say

Tandem Diabetes Care has shown a robust financial trajectory, with a notable 10–11% year-over-year growth anticipated in US pump shipments, driven by a strong renewal pump segment and a positive outlook on new patient starts. The management's emphasis on improving pharmacy access indicates a broader market expansion, facilitating more affordable options for new patients and enhancing overall sales channels. Additionally, revenue projections for 2026 and 2027 reflect slight increases, reinforcing a positive outlook on continued growth momentum in the durable insulin pump market.

Bears say

Tandem Diabetes Care's revenue forecast for 2026 has decreased slightly to $1.07 billion, with EBITDA projected to be negative, highlighting financial strain. The guidance for US revenue anticipates a headwind of approximately $70–$80 million from Pay-Go pump shipments, and there is a projected decline of 3% in new patient starts. Additionally, there are significant risks, including increased competitive pressures, challenges in securing profitable pharmacy channel contracts, and the uncertain profitability of the newly launched Mobi pump, all of which could adversely impact the company’s financial outlook.

TNDM has been analyzed by 18 analysts, with a consensus rating of Buy. 22% of analysts recommend a Strong Buy, 28% recommend Buy, 50% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Tandem Diabetes Care and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Tandem Diabetes Care (TNDM) Forecast

Analysts have given TNDM a Buy based on their latest research and market trends.

According to 18 analysts, TNDM has a Buy consensus rating as of Apr 23, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $28.89, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $28.89, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Tandem Diabetes Care (TNDM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.